DK3630164T3 - Dulaglutid til behandling af kronisk nyresygdom - Google Patents

Dulaglutid til behandling af kronisk nyresygdom Download PDF

Info

Publication number
DK3630164T3
DK3630164T3 DK18730908.3T DK18730908T DK3630164T3 DK 3630164 T3 DK3630164 T3 DK 3630164T3 DK 18730908 T DK18730908 T DK 18730908T DK 3630164 T3 DK3630164 T3 DK 3630164T3
Authority
DK
Denmark
Prior art keywords
dulaglutide
treatment
kidney disease
chronic kidney
chronic
Prior art date
Application number
DK18730908.3T
Other languages
English (en)
Other versions
DK3630164T5 (da
Inventor
Fady Talaat Botros
Mark Chandrakant Lakshmanan
Katherine Rose Tuttle
Alan George Zimmermann
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=62598054&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3630164(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of DK3630164T3 publication Critical patent/DK3630164T3/da
Application granted granted Critical
Publication of DK3630164T5 publication Critical patent/DK3630164T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/55—Protease inhibitors
    • A61K38/556—Angiotensin converting enzyme inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/76—Assays involving albumins other than in routine use for blocking surfaces or for anchoring haptens during immunisation
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/34—Genitourinary disorders
    • G01N2800/347—Renal failures; Glomerular diseases; Tubulointerstitial diseases, e.g. nephritic syndrome, glomerulonephritis; Renovascular diseases, e.g. renal artery occlusion, nephropathy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK18730908.3T 2017-06-01 2018-05-24 Dulaglutid til behandling af kronisk nyresygdom DK3630164T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762513556P 2017-06-01 2017-06-01
PCT/US2018/034278 WO2018222472A1 (en) 2017-06-01 2018-05-24 Dulaglutide for the treatment of chronic kidney disease

Publications (2)

Publication Number Publication Date
DK3630164T3 true DK3630164T3 (da) 2023-10-02
DK3630164T5 DK3630164T5 (da) 2024-09-02

Family

ID=62598054

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18730908.3T DK3630164T5 (da) 2017-06-01 2018-05-24 Dulaglutid til behandling af kronisk nyresygdom

Country Status (16)

Country Link
US (2) US20200171129A1 (da)
EP (2) EP3630164B1 (da)
JP (2) JP7191043B2 (da)
CN (1) CN110650747A (da)
CA (1) CA3065295C (da)
DK (1) DK3630164T5 (da)
ES (1) ES2963464T3 (da)
FI (1) FI3630164T3 (da)
HR (1) HRP20231093T1 (da)
HU (1) HUE063776T2 (da)
LT (1) LT3630164T (da)
PL (1) PL3630164T3 (da)
PT (1) PT3630164T (da)
RS (1) RS64666B1 (da)
SI (1) SI3630164T1 (da)
WO (1) WO2018222472A1 (da)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA50798A (fr) 2017-11-21 2020-09-30 Lilly Co Eli Procédés d'utilisation et compositions contenant du dulaglutide
CN113613629A (zh) * 2019-03-15 2021-11-05 伊莱利利公司 防腐的制剂
CA3056663C (en) 2019-04-05 2022-10-18 Jeffrey S. RIESMEYER Use of dulaglutide in reducing risk of cardiovascular events in patients with type 2 diabetes mellitus
US20230088005A1 (en) * 2020-01-30 2023-03-23 Eli Lilly And Company Therapeutic uses of dulaglutide
US20240197834A1 (en) * 2021-04-09 2024-06-20 Hanmi Pharm. Co., Ltd. Pharmaceutical composition for preventing or treating chronic renal disease including glucagon derivative
CN117143242B (zh) * 2023-10-30 2024-03-29 南京佰抗生物科技有限公司 抗Galectin-3蛋白的单克隆抗体组合物及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2371072T3 (es) 2003-06-12 2011-12-27 Eli Lilly And Company Proteínas de fusión análogas de glp-1.
KR20100020516A (ko) 2007-07-10 2010-02-22 일라이 릴리 앤드 캄파니 Ｇｌｐ-1-ｆｃ 융합 단백질 제제
MX341025B (es) * 2010-05-05 2016-08-04 Boehringer Ingelheim Int Gmbh * Terapia de combinacion.
AR090843A1 (es) * 2012-05-09 2014-12-10 Lilly Co Eli Tratamiento para diabetes comorbida con enfermedad renal cronica
JP2016522241A (ja) * 2013-06-21 2016-07-28 ノヴォ ノルディスク アー／エス インスリンで治療された及び／又は１型糖尿病に罹患している患者におけるｇｌｐ−１受容体作動薬の新規の使用

Also Published As

Publication number Publication date
LT3630164T (lt) 2023-10-25
DK3630164T5 (da) 2024-09-02
RS64666B1 (sr) 2023-11-30
JP7191043B2 (ja) 2022-12-16
EP4279925A2 (en) 2023-11-22
PL3630164T3 (pl) 2024-01-29
EP3630164A1 (en) 2020-04-08
CN110650747A (zh) 2020-01-03
US20200171129A1 (en) 2020-06-04
EP3630164B1 (en) 2023-08-23
US20240197835A1 (en) 2024-06-20
WO2018222472A1 (en) 2018-12-06
PT3630164T (pt) 2023-09-14
JP2020521765A (ja) 2020-07-27
JP2023002547A (ja) 2023-01-10
FI3630164T3 (fi) 2023-11-06
CA3065295C (en) 2023-08-29
ES2963464T3 (es) 2024-03-27
HUE063776T2 (hu) 2024-01-28
CA3065295A1 (en) 2018-12-06
EP4279925A3 (en) 2024-01-24
SI3630164T1 (sl) 2023-10-30
HRP20231093T1 (hr) 2023-12-22

Similar Documents

Publication Publication Date Title
DK3570844T3 (da) Azolopyrimidin til behandlingen af kræftrelaterede lidelser
IL271956A (en) Blood pump
DE112019002736A5 (de) Blutpumpe
DK3684439T3 (da) Blodpumpe
DK3501542T3 (da) Esketamin til behandling af depression
DK3349758T3 (da) Fremgangsmåder til behandling af arenaviridae-virusinfektioner
DK3912673T3 (da) Blodpumpe
DK3357523T3 (da) Blodpumpe
IL247111A0 (en) Preventive or therapeutic agent for kidney disease
DK3413948T3 (da) Blodpumpesystem
DK3474841T3 (da) Fremgangsmåder til behandling af ar+-brystkræft
DK3362066T3 (da) Kombinationsterapi til behandling af maligniteter
DK3240612T3 (da) Fremgangsmåder til behandling af nethindesygdomme
DK3390390T3 (da) Bipyrazolylderivater egnede til behandling af autoimmunsygdomme
DK3630164T5 (da) Dulaglutid til behandling af kronisk nyresygdom
DK3324824T3 (da) Fremgangsmåde til behandling af binokulare dysfunktioner
DE112017004905A5 (de) Blutpumpe
EP3876776C0 (en) CONNECTOR
HUE060517T2 (hu) Immunhiányos betegség kezelésére szolgáló eljárások
IL270552A (en) Volclospoin composition for treating proteinuric kidney disease
DK3468604T3 (da) Farmaceutiske kombinationer til behandling af cancer
DE112019001555A5 (de) Blutpumpe
DK3439661T3 (da) Fremgangsmåder til behandling af øjenlidelser
DK3585808T3 (da) Modificerede serpiner til behandlingen af bradykinin formidlet sygdom
DK3506956T3 (da) Lægemiddel, særlig til behandling af fistler